首页> 美国卫生研究院文献>Nucleic Acids Research >qEva-CRISPR: a method for quantitative evaluation of CRISPR/Cas-mediated genome editing in target and off-target sites
【2h】

qEva-CRISPR: a method for quantitative evaluation of CRISPR/Cas-mediated genome editing in target and off-target sites

机译:qEva-CRISPR:一种定量评估靶位点和脱靶位点中CRISPR / Cas介导的基因组编辑的方法

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Genome editing technology based on engineered nucleases has been increasingly applied for targeted modification of genes in a variety of cell types and organisms. However, the methods currently used for evaluating the editing efficiency still suffer from many limitations, including preferential detection of some mutation types, sensitivity to polymorphisms that hamper mismatch detection, lack of multiplex capability, or sensitivity to assay conditions. Here, we describe qEva-CRISPR, a new quantitative method that overcomes these limitations and allows simultaneous (multiplex) analysis of CRISPR/Cas9-induced modifications in a target and the corresponding off-targets or in several different targets. We demonstrate all of the advantages of the qEva-CRISPR method using a number of sgRNAs targeting the TP53, VEGFA, CCR5, EMX1 and HTT genes in different cell lines and under different experimental conditions. Unlike other methods, qEva-CRISPR detects all types of mutations, including point mutations and large deletions, and its sensitivity does not depend on the mutation type. Moreover, this approach allows for successful analysis of targets located in ‘difficult’ genomic regions. In conclusion, qEva-CRISPR may become a method of choice for unbiased sgRNA screening to evaluate experimental conditions that affect genome editing or to distinguish homology-directed repair from non-homologous end joining.
机译:基于工程核酸酶的基因组编辑技术已越来越多地应用于各种细胞类型和生物体中基因的靶向修饰。但是,当前用于评估编辑效率的方法仍然存在许多局限性,包括优先检测某些突变类型,对妨碍错配检测的多态性的敏感性,缺乏多重能力或对测定条件的敏感性。在这里,我们介绍qEva-CRISPR,一种新的定量方法,可克服这些局限性,并允许同时(多重)分析CRISPR / Cas9诱导的靶标和相应的脱靶标或几个不同靶标的修饰。我们展示了使用许多靶向TP53,VEGFA,CCR5,EMX1和HTT基因的sgRNA在不同细胞系和不同实验条件下qEva-CRISPR方法的所有优势。与其他方法不同,qEva-CRISPR可检测所有类型的突变,包括点突变和大缺失,其敏感性不取决于突变类型。而且,这种方法可以成功分析位于“困难”基因组区域的靶标。总之,qEva-CRISPR可能成为无偏sgRNA筛选的一种选择方法,以评估影响基因组编辑的实验条件或区分同源指导的修复与非同源末端连接。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号